**ALLERGAN INC** 

Form 4

February 13, 2014

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

0.5

Check this box if no longer subject to

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Expires: January 31, 2005

**OMB APPROVAL** 

Estimated average burden hours per

response...

Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * LAVIGNE LOUIS J JR			2. Issuer Name <b>and</b> Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer		
			ALLERGAN INC [AGN]	(Check all applicable)		
(Last) (First)		(Middle)	3. Date of Earliest Transaction			
			(Month/Day/Year)	X Director 10% Owner		
2525 DUPONT DRIVE			02/11/2014	Officer (give title Delow) Other (specify below)		
	(Street)		4. If Amendment, Date Original	6. Individual or Joint/Group Filing(Check		
			Filed(Month/Day/Year)	Applicable Line) _X_ Form filed by One Reporting Person		
IRVINE, CA 92612				Form filed by More than One Reporting Person		

(City)	(State)	(Zip) Tak	ole I - Non-	Derivative	Secu	rities Acquii	red, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securition Dispose (Instr. 3, 4	ed of (		5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(D)	Price	(Ilisti. 3 and 4)		
Common Stock	02/11/2014		M	11,400	A	\$ 54.32	24,123	D	
Common Stock	02/11/2014		S	11,400	D	\$ 122.41 (1)	12,723	D	
Common Stock	02/11/2014		M	11,400	A	\$ 46.66	24,123	D	
Common Stock	02/11/2014		S	11,400	D	\$ 122.41 (2)	12,723	D	
Common Stock	02/11/2014		M	11,400	A	\$ 61.98	24,123	D	
	02/11/2014		S	11,400	D	\$ 122.4	12,723	D	

### Edgar Filing: ALLERGAN INC - Form 4

Common Stock								
Common Stock	02/11/2014	M	9,000	A	\$ 51.715	21,723	D	
Common Stock	02/11/2014	S	9,000	D	\$ 122.401 (3)	12,723	D	
Common Stock	02/11/2014	M	11,400	A	\$ 60.6	24,123	D	
Common Stock	02/11/2014	S	11,400	D	\$ 122.349 (4)	12,723	D	
Common Stock						4,800	I	By Lavigne Survivor's Trust (5)
Common Stock						5,400	I	By Rachel Lavigne Exmpt Bypass Trust (6)
Common Stock						0	I	By Lavigne Family Trust (7)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exerci Expiration Da (Month/Day/Y	te	7. Title and a Underlying S (Instr. 3 and	Securi
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Nun of S
		02/11/2014		M	11,400	<u>(9)</u>	05/06/2018		11,

#### Edgar Filing: ALLERGAN INC - Form 4

Nonemployee Director Stock Option (Right to Buy)	\$ 54.32 (8)						Common Stock	
Nonemployee Director Stock Option (Right to Buy)	\$ 46.66	02/11/2014	M	11,400	<u>(9)</u>	04/30/2019	Common Stock	11,
Nonemployee Director Stock Option (Right to Buy)	\$ 61.98	02/11/2014	M	11,400	<u>(9)</u>	04/29/2020	Common Stock	11,
Nonemployee Director Stock Option (Right to Buy)	\$ 51.71	02/11/2014	M	9,000	05/02/2007	05/02/2016	Common Stock	9,0
Nonemployee Director Stock Option (Right to Buy)	\$ 60.6	02/11/2014	M	11,400	(10)	05/01/2017	Common Stock	11,

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
•	Director	10% Owner	Officer	Other			
LAVIGNE LOUIS J JR 2525 DUPONT DRIVE IRVINE, CA 92612	X						

### **Signatures**

/s/ Matthew J. Maletta, Attorney-In-Fact for Louis J.
Lavigne, Jr.

02/12/2014

\*\*Signature of Reporting Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.40 to \$122.457, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
- The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.40 to \$122.54, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
- (3) The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.37 to \$122.43, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the

Reporting Owners 3

#### Edgar Filing: ALLERGAN INC - Form 4

staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.

- The price reported in column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from \$122.32 to \$122.494, inclusive. The reporting person undertakes to provide Allergan, Inc., any security holder of Allergan, Inc., or the staff of the Securities Exchange Commission, upon request, the full information regarding the number of shares sold at each price within the range set forth in this footnote.
- (5) Shares held by the Louis Lavigne Survivor's Trust. Reporting Person is sole trustee of the Louis Lavigne Survivor's Trust.
- (6) Shares held by the Rachel Lavigne Exmpt Bypass Trust. Reporting Person is sole trustee of the Rachel Lavigne Exmpt Bypass Trust.
- (7) Shares held by the Lavigne Family Trust. Reporting Person is trustee of the Lavigne Family Trust.
- (8) The per share exercise price is the closing price of Allergan's common stock as of the date of grant.
- (9) Option is fully vested and exercisable upon the earlier to occur (i) the first anniversary of the grant date, or (ii) the annual meeting held during such calendar year at which one or more members of the board are standing for re-election following the date of grant.
- (10) Option is fully vested and exercisable on the date of the next regular annual meeting of stockholders of Allergan, Inc. at which directors are to be elected following the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.